A Phase 2 interventional study of Niraparib in Ovarian Neoplasms and Breast Neoplasms, sponsored by GlaxoSmithKline. Recruiting at 25 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.
Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 25th largest by planned enrollment, is one of 5 that started in 2021, is one of 18 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 29th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
University of Miami · Sites in United States, Nigeria
Ages 18+ · Women only
MedSIR · Sites in Spain
Ages 18+ · Women only
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+ · Women only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 37 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 41 across the 44 interventional studies. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
31 studies in Ovarian Neoplasms by GlaxoSmithKline: 5 open now, 7 under way, 5 of them phase 3. Of 22 finished, 16 (73%) have results posted.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 22nd largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2021, is one of 15 in phase 2, and was the 25th registered.
GlaxoSmithKline’s Ovarian Neoplasms studies by the year they started, since 1997.
2 of the studies testing niraparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT06594679Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing niraparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
Drug: Niraparib
Niraparib tablets or capsules will be given once a day via the oral route.
Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)
AEs, SAEs and AESI will be collected.
Time frame: Up to 5 years
Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status
The performance status will be assessed using ECOG scale, where Grade 0 (fully active), Grade 1 (restricted in physically strenuous activity), Grade 2 (ambulatory and capable of all self-care), Grade 3 (capable of only limited self-care) and Grade 4 (completely disabled). Number of participants with clinically significant changes in ECOG performance status will be summarized.
Time frame: Up to 5 years
Number of participants with clinically significant changes in hematology and clinical chemistry parameters
Blood samples will be collected for the analysis of hematology and clinical chemistry parameters.
Time frame: Up to 5 years
Number of participants with clinically significant changes in vital signs
Number of participants with clinically significant changes in vital signs will be assessed.
Time frame: Up to 5 years
Number of participants with clinically significant changes in physical examination
Number of participants with clinically significant changes in physical examination will be assessed.
Time frame: Up to 5 years
Number of participants with use of concomitant medications
Number of participants using concomitant medications will be assessed.
Time frame: Up to 5 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
No publications or documents are linked to this record.
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 68 months is above that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib